Compare ADT Inc (ADT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADT Inc vs Neurocrine Biosciences Inc — how do they compare? ADT Inc trades at $6.72 (market cap $5.07B), while Neurocrine Biosciences Inc trades at $176.83 (market cap $17.84B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.5× ADT Inc's market cap, and ADT Inc pays a 3.18% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| ADT | NBIX | |
|---|---|---|
Market Cap | $5.07B | $17.84B |
Sector | Industrials | Health |
52-Week High | $8.85 | $177.49 |
52-Week Low | $6.30 | $123.10 |
Enterprise Value | $12.62B | $16.93B |
Dividend Yield | 3.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADT trades at $6.91, up 1.17% today, with a bullish technical signal and consistent earnings beats. The company shows strong profitability with an 80.82% gross margin and 12.14% net margin, supported by positive news including recent industry awards and board participation in the Connectivity Standards Alliance. Cash flow from operations remains robust at $1.88 billion for 2025, though net cash flow was slightly negative.
Outlook is positive with analyst consensus leaning buy (47% buy ratings), but risks include high long-term debt of $7.51 billion and competitive pressures in home security. Revenue growth is stable, and valuation metrics like P/E of 8.88 suggest potential undervaluation, making it attractive for value-oriented investors mindful of leverage.
Neurocrine Biosciences (NBIX) trades at $174.1, showing modest daily movement with a slight decline of 0.09%. The stock exhibits strong bullish technical signals from moving averages and a consensus analyst buy rating of 86.49%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.94 surpassing the $1.22 estimate. Revenue growth is robust, climbing from $2.86B in 2025 to a projected $3.1B in 2026, supported by blockbuster products Ingrezza and Crenessity.
NBIX presents a favorable outlook with upward earnings momentum and strategic acquisitions strengthening its neuroscience portfolio. Key risks include pipeline execution challenges and competitive pressures. The consensus price target of $192.91 suggests approximately 11% upside potential from current levels, making it an attractive growth stock despite elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADT Inc
ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. ADT offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. It provides interactive home and business automation solutions designed to control access, react to movement, and sense carbon monoxide, flooding, changes in temperature or other environmental conditions, as well as address personal emergencies, such as injuries and medical emergencies. In addition, it offers professional monitoring of third-party devices through ADT Canopy platform. The product brands of the company are ADT and ADT Pulse, and Protection One brand.
Read more on ADT →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
